Last Updated: 25/03/2025
Accelerating vaccine development for Plasmodium vivax malaria
Objectives
In this project multiple complementary approaches will be used to select and prioritize P. vivax merozoite antigens for vaccine development using the mRNA vaccine platform.
Principal Institution
Principal Investigators / Focal Persons
Rationale and Abstract
Malaria due to P. vivax is a major global health problem, especially in the Asia-Pacific region. The development of an effective vaccine would greatly facilitate achieving malaria elimination goals set by the WHO. However, there are very few P. vivax vaccines in development and very few candidates have been identified.
External reference
Date
Jan 2025 — Dec 2027
Total Project Funding
$492,985
Funding Details
National Health and Medical Research Council (NHMRC) Australia, Australia
Grant ID: 2036102
AUD 749,647
Project Site
Related Resources
